Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 May 2010Website:
http://www.tgtherapeutics.comNext earnings report:
01 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:53:06 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
TGTX Latest News
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links.
TG Therapeutics, Inc. (NASDAQ:TGTX) will be holding its Q1 2024 Earnings Conference Call on May 1, 2024 at 8:30 AM ET. Key participants include Jenna Bosco, Michael Weiss, Adam Waldman, and Sean Power. Conference call participants include analysts from Evercore ISI, H.C. Wainwright, Jefferies, Ladenburg Thalmann, and B.
TG Therapeutics reported a quarterly loss of $0.07 per share, missing the Zacks Consensus Estimate of $0.03, compared to a loss of $0.28 per share in the same quarter last year.
Conference call scheduled for tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET.
TG Therapeutics introduced its multiple sclerosis medication BRIUMVI to the market in January 2023, receiving positive market reception and generating substantial revenue. The company possesses robust barriers to competition and patent safeguards for BRIUMVI, positioning it for potential expansion in 2024 and 2025.
TG Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript
TG Therapeutics (TGTX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.39 per share a year ago.
Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics CEO Mike Weiss recently presented at the J.P. Morgan Healthcare Conference, sharing positive updates on Briumvi's Q4 2023 net sales and revenue guidance for 2024. 2024 revenue guidance and the expense guidance suggest the company should become cash flow positive and profitable in the second half of the year. The company plans to start human trials for a subcutaneous version of Briumvi, aiming to improve convenience and compete with other treatments.
- 1(current)
- 2
What type of business is TG Therapeutics?
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
What sector is TG Therapeutics in?
TG Therapeutics is in the Healthcare sector
What industry is TG Therapeutics in?
TG Therapeutics is in the Biotechnology industry
What country is TG Therapeutics from?
TG Therapeutics is headquartered in United States
When did TG Therapeutics go public?
TG Therapeutics initial public offering (IPO) was on 03 May 2010
What is TG Therapeutics website?
https://www.tgtherapeutics.com
Is TG Therapeutics in the S&P 500?
No, TG Therapeutics is not included in the S&P 500 index
Is TG Therapeutics in the NASDAQ 100?
No, TG Therapeutics is not included in the NASDAQ 100 index
Is TG Therapeutics in the Dow Jones?
No, TG Therapeutics is not included in the Dow Jones index
When does TG Therapeutics report earnings?
The next expected earnings date for TG Therapeutics is 01 August 2024